UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 68

Sortiert nach

A translational pharmacokinetic/pharmacodynamic model to characterize bacterial kill in the presence of imipenem-relebactam

International journal of infectious diseases, 2019-12, Vol.89, p.55-61

2019

Volltextzugriff (PDF)

Population Pharmacokinetic Analysis for Imipenem–Relebactam in Healthy Volunteers and Patients With Bacterial Infections

CPT: pharmacometrics and systems pharmacology, 2019-10, Vol.8 (10), p.748-758

2019

Volltextzugriff (PDF)

Pharmacokinetics and Pharmacodynamics of Once-Daily versus Twice-Daily Raltegravir in Treatment-Naïve HIV-Infected Patients

Antimicrobial Agents and Chemotherapy, 2012-06, Vol.56 (6), p.3101-3106

2012

Volltextzugriff (PDF)

Population pharmacokinetic/pharmacodynamic assessment of imipenem/cilastatin/relebactam in patients with hospital‐acquired/ventilator‐associated bacterial pneumonia

Clinical and translational science, 2022-02, Vol.15 (2), p.396-408

2022

Volltextzugriff (PDF)

Molnupiravir: Mechanism of action, clinical, and translational science

Clinical and translational science, 2024-02, Vol.17 (2), p.e13732-n/a

2024

Volltextzugriff (PDF)

Ensemble modeling for aromatic production in Escherichia coli

PloS one, 2009-09, Vol.4 (9), p.e6903-e6903

2009

Volltextzugriff (PDF)

Raltegravir Has a Low Propensity To Cause Clinical Drug Interactions through Inhibition of Major Drug Transporters: an In Vitro Evaluation

Antimicrobial Agents and Chemotherapy, 2014-03, Vol.58 (3), p.1294-1301

2014

Volltextzugriff (PDF)

Population pharmacokinetics of tazobactam/ceftolozane in Japanese patients with complicated urinary tract infection and complicated intra-abdominal infection

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2019-03, Vol.25 (3), p.182-191

2019

Volltextzugriff (PDF)

Population pharmacokinetics of molnupiravir in adults with COVID‐19: Lack of clinically important exposure variation across individuals

CPT: pharmacometrics and systems pharmacology, 2023-12, Vol.12 (12), p.1859-1871

2023

Volltextzugriff (PDF)

Raltegravir pharmacokinetics in neonates following maternal dosing

Journal of acquired immune deficiency syndromes (1999), 2014-11, Vol.67 (3), p.310

2014

Volltextzugriff (PDF)

Patient‐Centric Clinical Pharmacology: A Journey from Discovery to Recovery

Clinical pharmacology and therapeutics, 2024-05, Vol.115 (5), p.928-930

2024

Volltextzugriff (PDF)

Single‐ and Multiple‐Dose Pharmacokinetics of Once‐Daily Formulations of Raltegravir

Clinical pharmacology in drug development, 2018-02, Vol.7 (2), p.196-206

2018

Volltextzugriff (PDF)

Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection

Antimicrobial agents and chemotherapy, 2016-10, Vol.60 (10), p.6234-6243

2016

Volltextzugriff (PDF)

Understanding effect site pharmacology of uprifosbuvir, a hepatitis C virus nucleoside inhibitor: Case study of a multidisciplinary modeling approach in drug development

CPT: pharmacometrics and systems pharmacology, 2021-07, Vol.10 (7), p.658-670

2021

Volltextzugriff (PDF)

A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study)

Clinical infectious diseases, 2021-12, Vol.73 (11), p.e4539-e4548

2021

Volltextzugriff (PDF)

Ensemble Modeling of Metabolic Networks

Biophysical journal, 2008-12, Vol.95 (12), p.5606-5617

2008

Volltextzugriff (PDF)

Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID‐19 Infection

Clinical pharmacology and therapeutics, 2020-12, Vol.108 (6), p.1135-1149

2020

Volltextzugriff (PDF)

Pharmacokinetics and Pharmacodynamics of Ceftolozane/Tazobactam in Critically Ill Patients With Augmented Renal Clearance

International journal of antimicrobial agents, 2021-04, Vol.57 (4), p.106299, Article 106299

2021

Volltextzugriff (PDF)

Factors Influencing COVID‐19 Risk: Insights From Molnupiravir Exposure‐Response Modeling of Clinical Outcomes

Clinical pharmacology and therapeutics, 2023-06, Vol.113 (6), p.1337-1345

2023

Volltextzugriff (PDF)

Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants

Antimicrobial agents and chemotherapy, 2018-09, Vol.62 (9)

2018

Volltextzugriff (PDF)

Simplification of Imipenem Dosing by Removal of Weight‐Based Adjustments

Journal of clinical pharmacology, 2019-05, Vol.59 (5), p.646-653

2019

Volltextzugriff (PDF)

Intrapulmonary Pharmacokinetics of Relebactam, a Novel β-Lactamase Inhibitor, Dosed in Combination with Imipenem-Cilastatin in Healthy Subjects

Antimicrobial agents and chemotherapy, 2018-03, Vol.62 (3)

2018

Volltextzugriff (PDF)

Ceftolozane-Tazobactam Population Pharmacokinetics and Dose Selection for Further Clinical Evaluation in Pediatric Patients with Complicated Urinary Tract or Complicated Intra-abdominal Infections

Antimicrobial agents and chemotherapy, 2019-06, Vol.63 (6)

2019

Volltextzugriff (PDF)

Pharmacokinetics and Safety of Single Intravenous Doses of Ceftolozane/Tazobactam in Children With Proven or Suspected Gram-Negative Infection

The Pediatric infectious disease journal, 2018-11, Vol.37 (11), p.1130-1136

2018

Volltextzugriff (PDF)

Exploring the Pharmacokinetic/Pharmacodynamic Relationship of Relebactam (MK-7655) in Combination with Imipenem in a Hollow-Fiber Infection Model

Antimicrobial agents and chemotherapy, 2018-05, Vol.62 (5)

2018

Volltextzugriff (PDF)

1 – 25 von 68

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(64)
Mit Volltextzugriff
(62)

Publikationsform

Sprache

Englisch
(67)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Science & Technology
(56)
Life Sciences & Biomedicine
(53)
Humans
(32)
Pharmacology & Pharmacy
(29)
Pharmacokinetics
(18)
Adult
(16)
Male
(14)
Female
(13)
Infectious Diseases
(13)
Microbiology
(11)
Drug Dosages
(10)
Pharmacology
(10)
Middle Aged
(9)
Imipenem
(8)
Models, Biological
(8)
Antibiotics
(7)
Young Adult
(7)
Adolescent
(6)
Anti-Bacterial Agents - Pharmacokinetics
(6)
Anti-Bacterial Agents - Therapeutic Use
(6)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

A translational pharmacokinetic/pharmacodynamic model to characterize bacterial kill in the presence of imipenem-relebactam

Population Pharmacokinetic Analysis for Imipenem–Relebactam in Healthy Volunteers and Patients With Bacterial Infections

Pharmacokinetics and Pharmacodynamics of Once-Daily versus Twice-Daily Raltegravir in Treatment-Naïve HIV-Infected Patients

Population pharmacokinetic/pharmacodynamic assessment of imipenem/cilastatin/relebactam in patients with hospital‐acquired/ventilator‐associated bacterial pneumonia

Molnupiravir: Mechanism of action, clinical, and translational science

Ensemble modeling for aromatic production in Escherichia coli

Raltegravir Has a Low Propensity To Cause Clinical Drug Interactions through Inhibition of Major Drug Transporters: an In Vitro Evaluation

Population pharmacokinetics of tazobactam/ceftolozane in Japanese patients with complicated urinary tract infection and complicated intra-abdominal infection

Population pharmacokinetics of molnupiravir in adults with COVID‐19: Lack of clinically important exposure variation across individuals

Raltegravir pharmacokinetics in neonates following maternal dosing

Patient‐Centric Clinical Pharmacology: A Journey from Discovery to Recovery

Single‐ and Multiple‐Dose Pharmacokinetics of Once‐Daily Formulations of Raltegravir

Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection

Understanding effect site pharmacology of uprifosbuvir, a hepatitis C virus nucleoside inhibitor: Case study of a multidisciplinary modeling approach in drug development

A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study)

Ensemble Modeling of Metabolic Networks

Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID‐19 Infection

Pharmacokinetics and Pharmacodynamics of Ceftolozane/Tazobactam in Critically Ill Patients With Augmented Renal Clearance

Factors Influencing COVID‐19 Risk: Insights From Molnupiravir Exposure‐Response Modeling of Clinical Outcomes

Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants

Simplification of Imipenem Dosing by Removal of Weight‐Based Adjustments

Intrapulmonary Pharmacokinetics of Relebactam, a Novel β-Lactamase Inhibitor, Dosed in Combination with Imipenem-Cilastatin in Healthy Subjects

Ceftolozane-Tazobactam Population Pharmacokinetics and Dose Selection for Further Clinical Evaluation in Pediatric Patients with Complicated Urinary Tract or Complicated Intra-abdominal Infections

Pharmacokinetics and Safety of Single Intravenous Doses of Ceftolozane/Tazobactam in Children With Proven or Suspected Gram-Negative Infection

Exploring the Pharmacokinetic/Pharmacodynamic Relationship of Relebactam (MK-7655) in Combination with Imipenem in a Hollow-Fiber Infection Model

Suchergebnisse filtern